BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24866769)

  • 1. MTBP is overexpressed in triple-negative breast cancer and contributes to its growth and survival.
    Grieb BC; Chen X; Eischen CM
    Mol Cancer Res; 2014 Sep; 12(9):1216-24. PubMed ID: 24866769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C9orf142 transcriptionally activates MTBP to drive progression and resistance to CDK4/6 inhibitor in triple-negative breast cancer.
    Liao L; Deng L; Zhang YL; Yang SY; Andriani L; Hu SY; Zhang FL; Shao ZM; Li DQ
    Clin Transl Med; 2023 Nov; 13(11):e1480. PubMed ID: 38009308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
    Li M; Li A; Zhou S; Lv H; Yang W
    J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.
    Brasó-Maristany F; Filosto S; Catchpole S; Marlow R; Quist J; Francesch-Domenech E; Plumb DA; Zakka L; Gazinska P; Liccardi G; Meier P; Gris-Oliver A; Cheang MC; Perdrix-Rosell A; Shafat M; Noël E; Patel N; McEachern K; Scaltriti M; Castel P; Noor F; Buus R; Mathew S; Watkins J; Serra V; Marra P; Grigoriadis A; Tutt AN
    Nat Med; 2016 Nov; 22(11):1303-1313. PubMed ID: 27775704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MTBP regulates cell survival and therapeutic sensitivity in TP53 wildtype glioblastomas.
    Song Y; Zhang L; Jiang Y; Hu T; Zhang D; Qiao Q; Wang R; Wang M; Han S
    Theranostics; 2019; 9(20):6019-6030. PubMed ID: 31534534
    [No Abstract]   [Full Text] [Related]  

  • 7. CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer.
    Black JL; Harrell JC; Leisner TM; Fellmeth MJ; George SD; Reinhold D; Baker NM; Jones CD; Der CJ; Perou CM; Parise LV
    Breast Cancer Res Treat; 2015 Jul; 152(2):337-46. PubMed ID: 26105795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer.
    Sheng J; Xue X; Jiang K
    Curr Mol Med; 2019; 19(2):147-155. PubMed ID: 30854965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferation-associated long noncoding RNA, TMPO-AS1, is a potential therapeutic target for triple-negative breast cancer.
    Mitobe Y; Ikeda K; Sato W; Kodama Y; Naito M; Gotoh N; Miyata K; Kataoka K; Sasaki H; Horie-Inoue K; Inoue S
    Cancer Sci; 2020 Jul; 111(7):2440-2450. PubMed ID: 32437068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin β1/ Src signaling in triple negative breast cancer cells.
    Hamurcu Z; Delibaşı N; Geçene S; Şener EF; Dönmez-Altuntaş H; Özkul Y; Canatan H; Ozpolat B
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):415-430. PubMed ID: 29288363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic protein MTBP interacts with MYC to promote tumorigenesis.
    Grieb BC; Gramling MW; Arrate MP; Chen X; Beauparlant SL; Haines DS; Xiao H; Eischen CM
    Cancer Res; 2014 Jul; 74(13):3591-602. PubMed ID: 24786788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TIPIN depletion leads to apoptosis in breast cancer cells.
    Baldeyron C; Brisson A; Tesson B; Némati F; Koundrioukoff S; Saliba E; De Koning L; Martel E; Ye M; Rigaill G; Meseure D; Nicolas A; Gentien D; Decaudin D; Debatisse M; Depil S; Cruzalegui F; Pierré A; Roman-Roman S; Tucker GC; Dubois T
    Mol Oncol; 2015 Oct; 9(8):1580-98. PubMed ID: 26004086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
    Guo GC; Wang JX; Han ML; Zhang LP; Li L
    Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
    Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
    J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC.
    Kim SJ; Ju JS; Kang MH; Eun JW; Kim YH; Raninga PV; Khanna KK; Győrffy B; Pack CG; Han HD; Lee HJ; Gong G; Shin Y; Mills GB; Eyun SI; Park YY
    Theranostics; 2020; 10(18):7974-7992. PubMed ID: 32724453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.
    Quintero M; Adamoski D; Reis LMD; Ascenção CFR; Oliveira KRS; Gonçalves KA; Dias MM; Carazzolle MF; Dias SMG
    BMC Cancer; 2017 Nov; 17(1):727. PubMed ID: 29115931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circ_0000520 contributes to triple-negative breast cancer progression through mediating the miR-1296/ZFX axis.
    Zhou Y; Ma G; Peng S; Tuo M; Li Y; Qin X; Yu Q; Kuang S; Cheng H; Li J
    Thorac Cancer; 2021 Sep; 12(18):2427-2438. PubMed ID: 34324278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High expression of FUSE binding protein 1 in breast cancer stimulates cell proliferation and diminishes drug sensitivity.
    Liu W; Xiong X; Chen W; Li X; Hua X; Liu Z; Zhang Z
    Int J Oncol; 2020 Aug; 57(2):488-499. PubMed ID: 32626933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAP7D3, a novel prognostic marker for triple-negative breast cancer, drives cell invasiveness and cancer-initiating cell properties to promote metastatic progression.
    Kuo WH; Chu PY; Wang CC; Huang PS; Chan SH
    Biol Direct; 2023 Aug; 18(1):44. PubMed ID: 37550720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.